The current financial score of GRI Bio Inc is 6.92. Its financial status is robust, and its operating efficiency is low.
The current valuation score of GRI Bio Inc is 8.69. Its current P/E ratio is -0.00, which is -14600.00% below the recent high of 0.09 and -211700.00% above the recent low of -1.27.
The current earnings forecast score of GRI Bio Inc is 8.00. The average price target is 153.50, with a high of 280.00 and a low of 27.00.
The current price momentum score of GRI Bio Inc is 7.75. Currently, the stock price is trading between the resistance level at 2.98 and the support level at 1.27, making it suitable for range-bound swing trading.
The current institutional shareholding score of GRI Bio Inc is 3.00. The latest institutional shareholding proportion is 0.75%, representing a quarter-over-quarter increase of 126.10%.
No risk assessment score is currently available for GRI Bio Inc. The Biotechnology & Medical Research industry's average is 3.98. The company's beta value is -1.18. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.